WINSTON-SALEM, N.C.,
May 2, 2019 /PRNewswire-PRWeb/ --
Precise Bio, a Regenerative Medicine company that is advancing the
use of bio-printed tissues and organs to enable new therapies,
today announced that it will present its cutting-edge bio-printing
and bio-fabrication technologies at the Ophthalmology Innovation
Summit (OIS), which is being held today in San Diego in conjunction with the American
Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.
OIS brings together clinical, capital and corporate leaders to
accelerate the development and commercialization of novel therapies
that can address unmet need in the treatment of ophthalmic disease.
Aryeh Batt, co-founder and Chief
Executive Officer of Precise Bio, will present the company's latest
achievements.
"Since establishing our dedicated ophthalmology business unit in
October 2018, we have made
significant progress in expanding our pipeline in multiple
ophthalmic indications," said Mr. Batt. "We are leveraging our
ability to manufacture ocular tissues and work with ocular cells
into preclinical studies in several indications, including
conditions that have significant unmet medical need. We hope to be
able to share promising results from some of these programs in the
coming months. We are pleased to have the opportunity to share our
progress with our colleagues at OIS."
Innovating New Treatments for LSCD-Related Conditions
In 2018 Precise Bio was the first company to transplant a
3D-printed cornea graft in animals. In 2019, the company initiated
preclinical studies to evaluate a bio-fabricated ocular surface
transplant (OST) for the treatment of limbal stem cell deficiency
(LSCD), a devastating condition that results in corneal
blindness.
Precise Bio's OST is an allogeneic engineered tissue comprising
limbal stem cells and other biomaterials designed for a simple
procedure that can be performed in a physician's office. The OST
program leverages the proven technologies that Precise Bio
developed for its cornea transplant program.
An Unparalleled Integrated 4D Bio-Fabrication Platform Enables
Innovation
Precise Bio's proprietary, laser-based 3D bio-printing technology,
together with a complete 4D bio-fabrication platform, enables
scale-up of traditional tissue engineering methods, making tissues
and organs available for clinical use. The technology will allow
cost-effective, reproducible and large-scale production of tissues
and organs that meet stringent quality control criteria. The
company's innovative 4D-bio-fabrication technology is a true
platform for innovation and includes cell expansion, bio-materials,
processes, 3D bio-printing and other required critical
technologies. Key advantages of this platform compared with other
bio-fabrication approaches are that it is able to generate complex
tissues in a highly reproducible manner and to apply lessons
learned from the fabrication of one tissue to the next. This allows
for rapid innovation and product development, and provides a
foundation on which to build a robust pipeline of proprietary
products with substantial clinical and commercial value. This
platform can solve critical limitations of existing 4D
bio-fabrication technologies and is paving the way for the
engineering of more complex tissues and organs.
Precise Bio is currently in discussions with pharmaceutical
companies to explore opportunities to leverage its technologies and
expertise to print ocular tissues and design an "eye on a chip" to
facilitate development of novel drugs for ophthalmic
indications.
"Precise Bio's 4D bio-fabrication production process opens the
door to developing a broad array of novel therapies for treating
ophthalmic indications that are not effectively addressed today,"
said Shay Soker, PhD, Professor at
the Wake Forest Institute of Regenerative Medicine (WFIRM) and a
co-founder of Precise Bio. "Ophthalmic tissues are complex,
comprising multiple cell types and layers. Precise Bio's technology
is the only one that accurately recapitulates the natural
complexity needed for normal ophthalmic function. Our technology
has the potential to revolutionize the treatment of multiple
ophthalmic diseases."
OIS Presentation Information
Session title: Innovation Showcase I
Presentation title: Bio-Fabricated Tissues and Organs for
Ophthalmology
Presenter: Aryeh Batt, co-founder
and CEO of Precise Bio
Presentation time: May 2, 2019,
9:58 a.m. PDT
Presentation location: Hilton San Diego Bayfront
About OIS
The Ophthalmology Innovation Summits facilitate meaningful
interactions and the exchange of information between clinical,
capital and corporate leaders to accelerate the development and
commercialization of novel therapies to address unmet needs. The
OIS even held in conjunction with the ASCRS Annual Meeting unites
over 500 industry, entrepreneurial and clinical leaders to
collaborate on the development and commercialization of innovative
drugs and devices to address unmet clinical needs.
About Precise Bio
Precise Bio is a regenerative medicine company developing and
commercializing break-through, proprietary regenerative medicine
technologies and cellular therapies that can transform patient care
across a wide range of medical indications. The company's
proprietary 3D bio-printing platform overcomes limitations of
existing extrusion and Ink-jet printers and paves the way for
printing of clinically viable tissues and organs.
The company was founded by Dr. Anthony
Atala, director of the Wake Forest Institute of Regenerative
Medicine (WFIRM), Prof. Shay Soker
from WFIRM and Mr. Aryeh Batt, who
developed the company's transformative and proprietary laser
printing technology, and serves as the company's CEO. The company
has established collaborations with world-class partners who bring
demonstrated expertise in complementary technologies that can be
leveraged on Precise Bio's platform in order to reproducibly
manufacture functional tissues.
Contacts
Corporate Contact – Precise Bio
Aryeh Batt, CEO
336-671-5571
Aryeh.batt(at)precise-bio.com
Media Contact – Lazar Partners
Erich Sandoval
917-497-2867
esandoval(at)lazarpartners.com
SOURCE Precise Bio